HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
- Status
- COMPLETED
- Phase
- NA
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
- Status
- UNKNOWN
- Phase
- N/A
The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE2
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.
- Status
- UNKNOWN
- Phase
- NA
Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors
- Status
- TERMINATED
- Phase
- N/A
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
- Status
- COMPLETED
- Phase
- PHASE2
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
- Status
- RECRUITING
- Phase
- PHASE1
Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation
- Status
- COMPLETED
- Phase
- N/A
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2